EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Overall side‐effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments

Gesamtbelastung durch Nebenwirkungen konsistent mit frühem Behandlungsabbruch wegen unerwünschter Ereignisse in vier klinischen Studien mit verschiedenen Krebsarten und Therapien

John Devin Peipert iD, Shaili Ganatra iD, Fengmin Zhao iD, Ju-Whei Lee, Jessica Roydhouse, Edward H Ip iD, Nathaniel O'Connell, Ruth C Carlos, Noah Graham, Mary Lou Smith, Ilana F Gareen, Ahmad A Tarhini und 6 weitere

Cancer · 15.10.2025 · 131 (S2)

DOI: 10.1002/cncr.70084 ↗

Auf einen Blick

In vier klinischen Studien war starke Belastung durch Nebenwirkungen im FACT-Item GP5 mit frühem Behandlungsabbruch wegen unerwünschter Ereignisse verbunden. Die Odds waren nach 3 Monaten in allen Studien erhöht.

Fragestellung

Erfasst das FACT-Item GP5 die Behandlungstoleranz, gemessen an frühem Behandlungsabbruch wegen unerwünschter Ereignisse, in vier Krebsstudien?

Methode

Analyse von Daten aus vier ECOG-ACRIN-Studien zu Brustkrebs, Melanom und chronischer lymphatischer Leukämie; GP5: starke vs. moderate/geringe Belastung; Auswertung des Zusammenhangs mit ETD nach 3 Monaten.

Ergebnisse

Nach 3 Monaten zeigte sich in allen Studien ein signifikanter Zusammenhang mit ETD: E1Z03 aOR 2,82 (95 %-KI 1,10–7,28), E1Z11 4,10 (1,69–10,00), E1609 6,77 (2,88–15,92), E1912 4,15 (1,64–10,49).

Schlussfolgerung der Autor:innen

Die Ergebnisse stützen frühere Befunde zum Zusammenhang zwischen starker Nebenwirkungsbelastung und frühem Behandlungsabbruch. GP5 könnte die Behandlungstoleranz abbilden, besonders bei frühem Auftreten von Belastung.

Kernaussagen

  • GP5 war in allen 4 Studien mit ETD assoziiert
  • aORs reichten von 2,82 bis 6,77
  • Starke Belastung durch Nebenwirkungen früh im Verlauf war besonders aussagekräftig

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 22.10.2025. Verfasst von John Devin Peipert und 17 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Patient Reported Outcomes Research, Department of Applied Health Sciences, University of Birmingham, Edgbaston Birmingham, UK. Hauptthemen laut MEDLINE: Neoplasms, Drug-Related Side Effects and Adverse Reactions, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Overall side‐effect impact, the aggregated experience of multiple toxicities, can be captured with the single Functional Assessment of Cancer Therapy (FACT) item GP5 (“I am bothered by side effects of treatment”). The objective of this study was to evaluate the ability of item GP5 to indicate treatment tolerability by examining its association with early treatment discontinuation (ETD) due to adverse events (AEs) in four cancer trials.

Methods

The authors analyzed data from four clinical trials coordinated by the ECOG‐ACRIN Cancer Research Group, covering breast cancer (E1Z11, all patients received anastrozole; E1Z03, compared anastrozole vs. exemestane), melanoma (E1609, compared ipilimumab vs. high‐dose interferon α), and chronic lymphocytic leukemia (E1912, compared ibrutinib–rituximab bs. standard chemoimmunotherapy). In each trial, GP5 responses were categorized as severe bother (i.e., “very much”/“quite a bit”) versus moderate/low bother (“somewhat”/“a little bit”/“not at all”).

Results

At 3 months, significant associations were observed in each trial, indicating approximately 2.8–6.8 times greater odds of ETD among patients reporting severe bother (E1Z03: adjusted odds ratio [aOR], 2.82; 95% confidence interval [95% CI], 1.10–7.28; E1Z11: aOR, 4.10; 95% CI, 1.69–10.00; E1609: aOR, 6.77; 95% CI, 2.88–15.92; E1912: aOR, 4.15; 95% CI, 1.64–10.49).

Conclusions

These results support prior research demonstrating an association between severe side‐effect bother, as reported on responses to the GP5 item, and ETD among patients with newly diagnosed multiple myeloma. The consistent association between GP5 responses and ETD suggests the GP5's ability to capture how well patients tolerate treatment, especially when side‐effect bother is observed early in the course of treatment, and signals an opportunity to develop interventions to promote treatment adherence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsDrug-Related Side Effects and Adverse ReactionsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleBreast NeoplasmsMaleMiddle AgedAgedNitrilesMelanomaAnastrozoleLeukemia, Lymphocytic, Chronic, B-CellIpilimumabClinical Trials as TopicRituximabPyrazolesPyrimidinesTriazolesAndrostadienes

Stichwörter der Autor:innen

clinical trialspatient‐reported outcomesquality of lifetolerability

Substanzen

NitrilesAnastrozoleexemestaneIpilimumabRituximabPyrazolesPyrimidinesTriazolesAndrostadienes

Autor:innen und Institutionen

  • Centre for Patient Reported Outcomes Research, Department of Applied Health Sciences, University of Birmingham, Edgbaston Birmingham, UK.
  • Department of Medical Social Sciences, Feinberg School of Medicine, Chicago, Illinois, USA.
  • Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Biostatistics Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
  • Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Department of Radiology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.

ORCID-Profile: John Devin Peipert, Shaili Ganatra, Fengmin Zhao, Edward H Ip

Förderung

  • NCI NIH HHS

Zitieren

APA

Peipert, J. D., Ganatra, S., Zhao, F., Lee, J. W., Roydhouse, J., Ip, E. H., O'Connell, N., Carlos, R. C., Graham, N., Smith, M. L., Gareen, I. F., Tarhini, A. A., Shanafelt, T., Stearns, V., Raper, P. J., Cella, D., Gray, R., & Wagner, L. I. (2025). Overall side‐effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments. Cancer, 131(S2). https://doi.org/10.1002/cncr.70084

Vancouver

Peipert JD, Ganatra S, Zhao F, Lee JW, Roydhouse J, Ip EH, et al. Overall side‐effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments. Cancer. 2025;131(S2). doi:10.1002/cncr.70084

BibTeX
@article{Peipert2025,
  author = {Peipert, John Devin and Ganatra, Shaili and Zhao, Fengmin and Lee, Ju-Whei and Roydhouse, Jessica and Ip, Edward H and O'Connell, Nathaniel and Carlos, Ruth C and Graham, Noah and Smith, Mary Lou and Gareen, Ilana F and Tarhini, Ahmad A and Shanafelt, Tait and Stearns, Vered and Raper, Pamela J and Cella, David and Gray, Robert and Wagner, Lynne I},
  title = {Overall side‐effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {S2},
  doi = {10.1002/cncr.70084}
}
Kostenlos starten →